Stifel Nicolaus analyst Jonathan Block reiterated a Buy rating on Cooper Co (NYSE: COO) on September 20 and set a price target of $280. The company’s shares closed on Friday at $268.93, close to its 52-week high of $270.64.
According to TipRanks.com, Block is a 5-star analyst with an average return of 23.4% and a 74.5% success rate. Block covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Idexx Laboratories, and Aratana.
Cooper Co has an analyst consensus of Strong Buy, with a price target consensus of $286.86, representing a 6.7% upside. In a report issued on September 21, Raymond James also maintained a Buy rating on the stock with a $300 price target.
.
See today’s analyst top recommended stocks >>
Cooper Co’s market cap is currently $13.2B and has a P/E ratio of 106.09. The company has a Price to Book ratio of 4.09.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Daniel Mcbride, the EVP, COO & Pres-CooperVision of COO sold 10,310 shares for a total of $2,726,387.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
The Cooper Cos, Inc. operates as a medical device company. It operates through the following business units: Cooper Vision and Cooper Surgical. The Cooper Vision business unit brings a refreshing perspective on vision care with a commitment to crafting quality lenses for contact lens wearers.
